Repotrectinib in Patients with ROS1 Fusion-Positive NSCLC: Data from the Pivotal Phase 1/2 TRIDENT-1 Trial
When: Tuesday, October 7 | 2 p.m. EST
ROS1-positive NSCLC represents only a small fraction of lung cancers, but for patients and care teams, treatment decisions carry enormous weight. Resistance, brain metastases, and limited targeted options make sequencing a constant challenge. That’s why the data from TRIDENT-1 on repotrectinib (Augtyro®) matter — they bring new clarity to how we can manage this population and extend time on therapy.
In this webinar, Michelle Amsler, MS, PharmD, BCOP (Bristol Myers Squibb), will share what you need to know about the drug’s mechanism, efficacy and safety outcomes, and how to place it alongside other ROS1 therapies in practice.
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
Upcoming Webinar
Additional NDC, due to Packaging Change of tivozanib (Fotivda®)
October 3, 2025 | 2:00 PM
Upcoming Webinar
Repotrectinib in Patients with ROS1 Fusion-Positive NSCLC
October 7, 2025 | 2:00 PM
